Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Maria Silvia Cona

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

M.S. Cona1, M. Lecchi2, S. Damian1, M. Del Vecchio1, C. Cimminiello1, S. Cresta3, M. Duca3, A. Necchi1, D. Signorelli3, M. Poggi3, D. Raggi2, R. Ratta2, P. Verderio2, F.G.M. de Braud1, M. Di Nicola3

Author affiliations

  • 1 Dpt Medical Oncology And Hematology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Dpt Of Applied Research And Technological Development, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Dpt Medical Oncology And Hematology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
More

Resources

Abstract 5742

Background

The advent of immune check point inhibitors (ICIs) has improved prognosis of various cancers. To better select responding patients (pts) and for a more accurate management of economic resources, biological and biochemical factors have been investigated. To date, no predictive biomarkers have been validated. The aim of this study is to identify manageable and routinely detectable parameters to use in clinical practice to select pts with higher change of response to ICIs.

Methods

271 consecutive metastatic solid tumor pts treated in our Institute from 2013 to 2017 with ICIs were evaluated for baseline LDH serum level, ECOG score, age, type of ICI, number of metastatic sites, histology and sex. A training and validation set were used to build and test models, respectively. Variables’ effects were assessed through odds ratio estimates (OR) and area under the receive operating characteristic curves (AUC), from univariate and multivariate logistic regression models. The validated estimates were used to develop an Excel algorithm to calculate probabilities of response.

Results

As best response, 55.4% of pts achieved disease control and 44.7% had progressive disease. On the training set, LDH, age and ECOG showed a significant OR (p:<.001, 0.009, 0.042, respectively) and were combined in a multivariate model with an AUC of 0.771 (95%CI: 0.701;0.842). These results were statistically validated on the validation set (AUC: 0.685, 95%CI: 0.569;0.801). By fitting the validated model on all pts, the 3 variables retained a significant OR and a satisfactory cross-validated AUC.

Conclusions

We confirm, as reported in literature, that baseline LDH serum levels are inversely associated with response probability. It’s reasonable to jointly consider age and ECOG, which give a significant contribution to model performance. The developed algorithm, once validated on an independent prospective series, might be a base to guide physicians in clinical practice to better plan ICI therapy tailored on pts characteristics.

Clinical trial identification

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale Tumori.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings